Bottom line
Retatrutide + Cagrilintide is marketed as "Reta/Cagri," "RetaCag," and sometimes the imprecise vendor slang "GLP-3 + Cagrilintide." Observed listings claim 12.5/2.5, 10/2.5, 20/4, or 10/10 mg. No published study of these seller-created fixed mixtures was identified.
No established or recommended human dose. Reported amounts below are market observations, not guidance.
Name and formulation variability
| Observed source/date | Claimed components | Claimed amounts | Verification limits |
|---|---|---|---|
| Ameano Peptides (2026) | Retatrutide, Cagrilintide | 12.5 / 2.5 mg | Vendor-declared; identity and contents not independently verified |
| Aventris Labs (2026) | Retatrutide, Cagrilintide | 10 / 2.5 mg | Vendor-declared market observation |
| Cenexa Labs (2026) | Retatrutide, Cagrilintide | 20 / 4 mg | Vendor-declared market observation |
| Peptimed (2026) | Retatrutide, Cagrilintide | 10 / 10 mg | Vendor-declared market observation |
The component ratio varies from equal mass to strongly retatrutide-weighted. "GLP-3" is vendor slang, not a recognized generic name for retatrutide.
Component evidence
| Component | Separate evidence | Evidence for combination | Compatibility/stability evidence |
|---|---|---|---|
| Retatrutide | See component monograph; A clinical-stage candidate with scientific or public relevance. Investigation is not approval, and a studied exposure is not a recommendation. Definition source: Scope and selection methodology · Glossary findings do not establish this mixture | None identified for the marketed mixture | None identified |
| Cagrilintide | See component monograph; investigational findings do not establish this mixture | None identified for the marketed mixture | None identified |
Combination-specific studies
No published peer-reviewed study testing the observed seller-created Retatrutide + Cagrilintide fixed mixtures was identified. Separate development programs do not validate an unverified combined product.
Safety and interaction uncertainties
No combination-specific human safety, interaction, How a substance is absorbed, distributed, metabolized, and eliminated by the body; atlas pages report pharmacokinetic data such as half-life, metabolism, and clearance. Definition source: Neutral gloss; usage context: Routes, devices, and absorption primer · Glossary, or toxicology dataset was identified for these marketed mixtures.
Wide ratio variance prevents the name from identifying a reproducible formulation.
Modified, acylated peptides create analytical and stability questions not answered by a total-mass listing.
Identity, purity, sterility, and co-formulation compatibility cannot be inferred from seller pages.
Regulatory and product-quality notes
"RetaCag" and "GLP-3 + Cagrilintide" are market slang, not regulatory formulation names.
Regulatory and development status must be assessed for each exact substance and product; it does not transfer to a combined vendor vial.
The cited pages are low-quality market observations and do not establish approval or suitability for humans.
Evidence gaps
No controlled study of the marketed fixed mixture
No standardized ratio or name
No independent identity and content comparison
No published co-formulation compatibility or stability study
Sources
Ameano Peptides. Retatrutide + Cagrilintide market page. https://ameanopeptides.com/ accessed 2026-08-08.
Aventris Labs. Retatrutide + Cagrilintide market page. https://aventrislabs.com/ accessed 2026-08-08.
Cenexa Labs. RetaCag market page. https://cenexalabs.com/ accessed 2026-08-08.
Peptimed. Reta/Cagri market page. https://peptimed.com/ accessed 2026-08-08.